 | |
 Laurus Labs manufacturing facility in Visakhapatnam | |
| Company type | Public |
|---|---|
| Traded as | NSE: LAURUSLABS BSE: 540222 |
| Industry | Pharmaceuticals |
| Founded | 2005; 19 years ago (2005) |
| Founder | Satyanarayana Chava |
| Headquarters | Hyderabad, Telangana, India |
| Number of locations | 6 |
| Area served | Global |
| Key people |
|
| Products | Formulations Active pharmaceutical ingredients Speciality Chemicals, Agro Chemicals |
| Services | Custom synthesis Contract development and manufacturing organization Fermentation |
| Revenue |  ₹6,040 crore (US$720 million) (FY23) |
| Net income |  ₹796 crore (US$95 million) (FY23) |
| Number of employees | 5,700 (2022) |
| Divisions | Laurus Generics Laurus Synthesis Laurus Bio |
| Subsidiaries |
|
| Website | www |
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava.
Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States.
Business divisions
The company has 4 business divisions, which are generic formulation (FDF), generic APIs, contract development and manufacturing (CDMO)-Synthesis, biotechnology and speciality chemicals.
Generic formulation (FDF)
In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.
Generic APIs
Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest HiPotent API capacities in India The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS, and hydroxychloroquine tablets, which are used to treat certain types of malaria.
The company also manufactures oncology and cardiovascular APIs. Laurus Labs supplies (APIs) to nine of the 10 largest generic pharma companies in the world.
CDMO-Synthesis
Laurus Synthesis is the company's CDMO subsidiary. The US, European Union and Japan are the three most important markets for Laurus Synthesis.
Laurus Bio
Laurus Bio is the company's biotechnology subsidiary. Laurus Labs entered the biotechnology sector in 2020, by acquiring the Indian biotech company, Richcore. Post the acquisition, Richcore was renamed to Laurus Bio Pvt Ltd, and became a subsidiary of Laurus Labs. As of 2022, Laurus Bio has put into operation a 180 kilolitre fermentation capacity in food proteins.
References
- "Laurus Labs Ltd". Bloomberg. Retrieved 17 April 2020.
- "Hyderabad-based Laurus Labs receives licence to manufacture 2DG". Telangana Today. 2 July 2021. Retrieved 27 January 2023.
- "Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts". Moneycontrol. Retrieved 17 April 2020.
- "Laurus Labs: A hot startup in the pharma sector". Forbes India. Retrieved 17 April 2020.
- ^ "Laurus Labs Q4 net slumps". The Hindu. 27 April 2023. Retrieved 27 June 2023.
- "India's Laurus Labs says four employees died in fire incident". Reuters. 27 December 2022. Retrieved 27 January 2023.
- "Laurus Labs Share Price: Company forays into Lucrative Biotech Space". Zee Business. 27 November 2020. Retrieved 27 November 2020.
- Sharma, Neetu Chandra (15 March 2022). "How Satyanarayana Chava Grew Laurus Labs". Business Today. Retrieved 29 March 2022.
- Trivedi, Isha. "Laurus Labs strikes gold by moving up the value chain. But there's a steeper climb ahead". The Economic Times. Retrieved 19 October 2020.
- "Laurus Labs Limited: Annual Report 2021-22" (PDF). Laurus Labs. 2022. p. 3. Retrieved 16 June 2022.
- "Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US". Moneycontrol. Retrieved 17 April 2020.
- Laurus Labs. "Investor Presentation" (PDF).
- "Laurus Labs eyes bigger play in generic formulations segment". Times of India. Retrieved 17 April 2020.
- "Laurus Labs gets USFDA nod for HIV drug". Economic Times Health. Retrieved 17 April 2020.
- "Laurus Labs is ready to flood the US with cheap HIV drugs". Livemint. Retrieved 17 April 2020.
- "Laurus Labs gets USFDA nod for malaria tablets". The Hindu Business Line. Retrieved 17 April 2020.
- ^ ET Bureau (29 March 2022). "ET Emerging Company of the Year 2021: Laurus Labs-A pharma company beats the virus trap to make it big". The Economic Times. Retrieved 24 July 2022.
- Capital Market (12 January 2021). "Laurus Labs arm incorporates wholly-owned unit". Business Standard India. Retrieved 24 July 2022.
- "Laurus Labs Limited: Annual Report 2021-22" (PDF). Laurus Labs. 2022. p. 6. Retrieved 17 July 2022.
- ^ Ramarathinam, Ashwin (25 November 2020). "Laurus Labs buys 73% stake in Biotech firm Richcore Lifesciences for Rs247 crore". mint. Retrieved 29 March 2022.
- "Investors Presentation of the company" (PDF). www.nseindia.com/. NSE Website - Investors Presentation of the company. Quotes.
- "Laurus Labs Limited: Annual Report 2021-22" (PDF). Laurus Labs. 2022. p. 7. Retrieved 13 July 2013.
External links
- "Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%". www.indiainfoline.com. Retrieved 20 January 2021.
- "Laurus Labs: Diversification to speed up in FY23; add on declines". Moneycontrol. 3 May 2021. Retrieved 3 May 2021.
- "Laurus Labs is already halfway past its $1 billion revenue target and has new capacities and products to back up its growth plan". Moneycontrol. 4 May 2021. Retrieved 4 May 2021.
